The use of any investigational medication or device in the 30 days prior to screening and throughout the study is prohibited.
Use of any prohibited concomitant medications: immunotherapy, 5 alpha reductase inhibitors, spironolactone, diethystilbestrol (DES), ketoconazole, newer medications targeting ARs; NOTE: the concurrent use of all other drugs, over-the-counter medications, or alternative therapies must be documented; the principal investigator should be alerted if the patient is taking any agent that interacts with CYP450 system
Patients who need to continue treatment with any prohibited medications
Patients who have not completed the appropriate washout period for the prohibited medications
Current use of a prohibited medication
Use of any prohibited medication within the timeframes
Chronic use of moderate or strong CYP3A4 modulators (inhibitor or inducer) or any other prohibited medications. A washout period of 7 days is required prior to venetoclax dosing if a prohibited medication is discontinued.
Current use of a prohibited medication as described
A list of prohibited medications on study are listed
Current use, or up to 14 days prior use, of certain prohibited medication or requires any of these medications during treatment phase.
Requiring treatment with any of the prohibited concomitant medications listed that cannot be stopped for the duration of trial participation
Current use of a prohibited medication while on dabrafenib/trametinib
Use of other prohibited medications within 7 days prior to cycle 1 day 1 on study (Arms B and C only) (see Appendix 1 for list of prohibited medications)
Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation
Use of a prohibited concomitant medication that cannot be safely discontinued or substituted.
Current use of a prohibited medication or requires any of these medications during treatment with the investigational drugs. This includes excluding current medications known or suspected to be associated QT prolongation. In addition, any subject who is expected to require a QT prolonging medication while on trial should not be enrolled.
Unable to discontinue the use of prohibited medications
Subjects taking prohibited medications with the exception of systemic corticosteroids. A washout period of at least 5 elimination half-lives (or as clinically indicated) should occur for prohibited medications prior to the start of treatment
Receiving or anticipated to receive medications prohibited in the protocol.
Patients receiving prohibited medications; prohibited medications or those to be used with caution (i.e., ketoconazole, itraconazole, ritonavir, macrolide antibiotics, erythromycin phenytoin, phenobarbital, carbamazapine, and valproic acid)
Current or previous use of a prohibited medication as listed in the protocol;
Current use of any of the prohibited drugs
Subjects taking prohibited medications; a washout period of prohibited medications for a period of at least two weeks or as clinically indicated should occur prior to the start of treatment
Current use of a prohibited medication
Use of prohibited medications that cannot be changed to an alternative therapy
Use of any prohibited concomitant medications within the prior 2 weeks
Use of any prohibited concomitant medications within 7 days of registration
Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation
Current use of a prohibited medication
Current use of a prohibited medication including anticoagulants or platelet inhibitors or expected to require any of these medications during treatment with the investigational drug
Treatment with prohibited medications
Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK3326595.
Be taking or require the use of prohibited medications
Use of prohibited drugs
Current use of a prohibited medication or requires any of these medications during treatment with study drug
Current use of prohibited medications
Current use of a prohibited medication
Treatment with prohibited medications less than or equal to 14 days prior to\n             treatment with rociletinib
Current or planned use of prohibited meds
Current use of a prohibited medication
Current use of a prohibited medication or requires any of these medications during treatment with the investigational drugs (details will be available in the protocol). This includes excluding current medications known or suspected to be associated QT prolongation. In addition, any subject who may require a QT prolonging medication while on trial should not be enrolled.
Current use of a prohibited medication including anticoagulants or platelet inhibitors or expected to require any of these medications during treatment with the investigational drug.
Patients receiving prohibited concomitant medications at the start of the study
Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK2820151.
Current use of prohibited medication(s) or requirement for prohibited medications during study as per the study protocol. Use of anticoagulants such as warfarin is permitted; however, international normalization ratio (INR) must be monitored according to local institutional practice.
Current use of any of the drugs (prohibited concomitant medications)
Use of any prohibited concomitant medications within 30 days prior to cycle 1, day 1
Current use of a prohibited medication
Use of other prohibited medications within 5 half-lives or 14 days prior to the first dose of study drugs or requires any of these medications while receiving medication on this study
Current use of a prohibited medication while on dabrafenib
Willing and able to discontinue prohibited concomitant medications and/or treatments for CTCL during the study
Current use of a prohibited medication or requires any of these medications during treatment with lapatinib prior to study entry
Any prohibited concomitant medications for therapy with afatinib or gefitinib
Is on any specifically prohibited medication or requires any of these medications during treatment with pazopanib
Current use of a prohibited medication or expected to require any of these medications during treatment with study treatment.
Receiving, or planning to receive, any of the medications listed in the Prohibited Medications during conduct of the study
Use of prohibited medications:
Treatment with prohibited medications less than or equal to 14 days prior to first day of study treatment
Current use of a prohibited medication or expected to require any of these medications during treatment with the investigational drug
A condition that is expected to require concomitant use of any medication listed as prohibited while on study.
Use of any prohibited concomitant medications (washout period of 1 week)
Current use of a prohibited medication per protocol or expected to require any of these medications during treatment with study drug.
The following medications are prohibited during the study:\r\n* Immunosuppressive agents (except to treat a drug-related adverse event) are prohibited during the study\r\n* Systemic corticosteroids > 10 mg daily prednisone equivalent\r\n* Any concurrent chemotherapy, hormonal therapy, immunotherapy, or investigational agents for treatment of cancer are prohibited during the study
Concurrent treatment with protocol-defined prohibited medications (refer to protocol for details)
Requiring treatment with any of the prohibited concomitant medications
Any prohibited medication(s) or herbal preparation as described in the protocol or requires any of these medications during the study.
Current use of a prohibited medication as described in the protocol.
Current use of a prohibited medication
Current use of a prohibited medication or herbal preparation or requires any of these medications during the study.
The systemic use of the following therapies are prohibited within 28 days of first dose of study medication, or longer where indicated:
Must not be on any prohibited medications.
Use of any prohibited medications within 14 days of the first dose of study medication
Current use of a prohibited medication or requires any of these medications during treatment with study drug.
Patients who need to continue treatment with any prohibited medications
Patients who have not completed the appropriate washout period for the prohibited medications
Current use of a prohibited medication or requires any of these medications during treatment with GSK1120212